5 Stocks in the News…
Things like news releases or earnings announcements can be important triggers to look for… And we found 5 stocks that appear to be in an excellent position to deliver high-probability trading opportunities in the days and weeks ahead.

Click Here to Get ALL 5 Stocks.
>>>
pixel
Julie McHugh net worth and biography

Julie McHugh Biography and Net Worth

Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc. Before that she served as company group chairman for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade® (infliximab), Prezista® (darunavir) and Intelence® (etravirine), and she was responsible for oversight of a research and development portfolio including compounds targeting HIV, hepatitis C, and tuberculosis. Prior to joining Centocor, Inc., Ms. McHugh led the marketing communications for gastrointestinal drug Prilosec® (omeprazole) at Astra-Merck Inc. She currently chairs the board of visitors for the Smeal College of Business of Pennsylvania State University as well as serves on the board of directors of Aerie Pharmaceuticals, Inc., Lantheus Holdings, Inc. and Trevena, Inc., all publicly held companies, and The New Xellia Group, a privately held company. She previously served on the board of directors for ViroPharma Inc., Epirus Biopharmaceuticals, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute. Ms. McHugh received her M.B.A. degree from St. Joseph’s University and her B.S. degree from Pennsylvania State University.

What is Julie McHugh's net worth?

The estimated net worth of Julie McHugh is at least $1.47 million as of September 8th, 2020. Ms. McHugh owns 123,107 shares of Ironwood Pharmaceuticals stock worth more than $1,472,360 as of December 1st. This net worth estimate does not reflect any other investments that Ms. McHugh may own. Additionally, Ms. McHugh receives a salary of $155,000.00 as Director at Ironwood Pharmaceuticals. Learn More about Julie McHugh's net worth.

How old is Julie McHugh?

Ms. McHugh is currently 58 years old. There are 6 older executives and no younger executives at Ironwood Pharmaceuticals. The oldest executive at Ironwood Pharmaceuticals is Mr. Thomas A. McCourt, CEO & Director, who is 65 years old. Learn More on Julie McHugh's age.

What is Julie McHugh's salary?

As the Director of Ironwood Pharmaceuticals, Inc., Ms. McHugh earns $155,000.00 per year. There are 5 executives that earn more than Ms. McHugh. The highest earning executive at Ironwood Pharmaceuticals is Mr. Thomas A. McCourt, CEO & Director, who commands a salary of $1,570,000.00 per year. Learn More on Julie McHugh's salary.

How do I contact Julie McHugh?

The corporate mailing address for Ms. McHugh and other Ironwood Pharmaceuticals executives is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. Ironwood Pharmaceuticals can also be reached via phone at (617) 621-7722 and via email at [email protected] Learn More on Julie McHugh's contact information.

Has Julie McHugh been buying or selling shares of Ironwood Pharmaceuticals?

Julie McHugh has not been actively trading shares of Ironwood Pharmaceuticals within the last three months. Most recently, Julie Mchugh sold 10,000 shares of the business's stock in a transaction on Tuesday, December 14th. The shares were sold at an average price of $11.02, for a transaction totalling $110,200.00. Learn More on Julie McHugh's trading history.

Who are Ironwood Pharmaceuticals' active insiders?

Ironwood Pharmaceuticals' insider roster includes Mark Currie (Director), Alexander Denner (Director), Thomas McCourt (CEO), Julie McHugh (Director), Jason Rickard (COO), Michael Shetzline (CMO), and Ronald Silver (Insider). Learn More on Ironwood Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Ironwood Pharmaceuticals?

During the last twelve months, insiders at the biotechnology company sold shares 12 times. They sold a total of 470,787 shares worth more than $5,502,789.36. The most recent insider tranaction occured on October, 3rd when CEO Thomas A Mccourt sold 18,899 shares worth more than $196,738.59. Insiders at Ironwood Pharmaceuticals own 13.1 % of the company. Learn More about insider trades at Ironwood Pharmaceuticals.

Information on this page was last updated on 10/3/2022.

Julie McHugh Insider Trading History at Ironwood Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2021Sell10,000$11.02$110,200.00View SEC Filing Icon  
9/8/2020Sell7,950$9.77$77,671.50123,107View SEC Filing Icon  
6/5/2019Sell1,500$11.26$16,890.00109,337View SEC Filing Icon  
9/5/2018Sell1,500$19.10$28,650.0091,131View SEC Filing Icon  
6/5/2018Sell1,500$17.62$26,430.0092,631View SEC Filing Icon  
3/5/2018Sell1,500$14.06$21,090.0077,908View SEC Filing Icon  
12/4/2017Sell1,500$16.45$24,675.0079,408View SEC Filing Icon  
9/5/2017Sell1,500$16.16$24,240.0080,908View SEC Filing Icon  
See Full Table

Julie McHugh Buying and Selling Activity at Ironwood Pharmaceuticals

This chart shows Julie Mchugh's buying and selling at Ironwood Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ironwood Pharmaceuticals Company Overview

Ironwood Pharmaceuticals logo
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $11.96
Low: $11.87
High: $12.11

50 Day Range

MA: $10.91
Low: $9.90
High: $12.11

2 Week Range

Now: $11.96
Low: $9.73
High: $12.95

Volume

1,501,335 shs

Average Volume

2,603,400 shs

Market Capitalization

$1.83 billion

P/E Ratio

12.59

Dividend Yield

N/A

Beta

0.99
5 Stocks in the News…
Things like news releases or earnings announcements can be important triggers to look for… And we found 5 stocks that appear to be in an excellent position to deliver high-probability trading opportunities in the days and weeks ahead.

Click Here to Get ALL 5 Stocks.
>>>
pixel